Resume

Sign in

Histotechnologist

Location:
Olympia, Washington, United States
Salary:
Negotiable
Posted:
October 25, 2016

Contact this candidate

Resume:

OBJECTIVE

Continued personal commitment to provide high standards of integrity in supporting and improving medical technology to aid in freeing patients from suffering and improving quality of life.

PROFESSIONAL

SNBL USA, Ltd. - Everett, WA

2008-2016

Essential Job Functions:

Maintains Good Laboratory Practices (GLP)

Delegates and supervises the histology laboratory personnel and pathology associates in the appropriate responsibilities and daily activities associated with slide preparation in compliance with the requirements of study protocols, SOPs and GLP requirements.

Initiates, acquires and installs all equipment and instruments necessary to adequately perform histology, immunohistochemistry, plastic, electron microtomy and other related services.

Develops and implements laboratory policies, Standing Operating Procedures (SOP) and validation/qualification requirements, ensuring compliance with the FDA (GLP), L&I, and other regulatory agencies for study validity.

Identifies, troubleshoots and resolves problems with personnel, equipment and procedures.

Establishes histology workload schedules including but not limited to embedding, microtomy, staining and other technical duties as required.

Supervises all administrative responsibilities as related to staffing including analyzing current and future staffing needs.

Maintains inventory control

Conducts annual staff evaluations and enforces safety regulations

Evaluates capital purchases and contracts with appropriate vendors, writes purchasing proposals and constructs budget requirements.

Creates and implements training programs to establish and maintain quality using uniform methods in procedures and current techniques.

Reviews equipment performances and maintains appropriate documentation

Conducts quality control throughout histology preparations

Performs histology processes such as trimming, tissue processing, embedding, microtomy, frozen section microtomy, immunohistochemistry and in situ hybridization.

Create and implement optimization and validation of antibodies for immunohistochemistry as well as trouble shooting and interpreting results.

Novartis (formerly Chiron Corporation) – Emeryville, CA

2004-2008

Senior Research Specialist II, BioPharma-Translational Medicine

Essential Job Functions:

Developed, validated, maintained and expanded IHC biomarker panels for clinical trials, In Vivo Pharmacology and Target Identification.

Evaluated and created Target ID – IHC packets for research management review and external collaboration presentations.

Evaluated the therapeutic and biological effects of CHIR258 on patient samples from phase-1 clinical trials for tumor malignancies.

Evaluated the effects of antibody and small molecules therapeutics in POC animal studies.

Created tissue micro arrays of cancer indications and cell pellet controls for use in target validation, immunolocalization and epidemiology surveys.

Created methodologies and procedures for use in characterizing and validating tool antibodies.

Performed Cell culture techniques for preparation of cell pellet controls for use in IHC protocols.

Actively participated in project sub teams, departmental and lab meetings.

Contributed to experimental pathology portions of publications.

DNAX Research, Inc. - Palo Alto, CA

2003-2004

Scientist II

Essential Job Functions:

Developed novel monoclonal antibody reagents for use in sophisticated immunohistochemical procedures on frozen and paraffin embedded tissues to include same species immunohistochemistry, tissue cross reactivity studies, and double labeling immunohistochemistry.

Evaluated new methodologies to improve overall throughput of immunohistochemical procedures to include epitope retrieval and signal amplification procedures, digital microscopy and experimental design.

Developed and implemented new immunohistochemistry procedures to use with laser capture micro dissection.

Developed a novel technique to created frozen tissue micro arrays.

Prepared reports, presented data, and contributed to scientific discussion at project team meetings.

Genentech, Inc. – South San Francisco, CA

1997-2003

Senior Research Associate, Anatomic Pathology

Essential Job Functions:

Developed, validated and implemented comprehensive immunohistochemical techniques to include tyramide signal amplification, mouse-on-mouse, immunohistochemical multiple labeling and in situ hybridization -- immunohistochemical dual labeling.

Evaluated the incidence of Her2 over expression in human tumors.

Performed an immunohistochemistry survey for the expression of CD40 in Malignant Neoplasms.

Developed and validated protocols for the immunolocalization of VEGR and its receptors [Flt-1 and KDR/Flk-1] in formalin fixed paraffin embedded tissue samples.

Performed a comparative analysis of VEGF mRNA and HIF-1a protein expression in tissue microarrays.

Developed and validated protocols for the immunolocalization of Apo2L/TRAIL and its receptors in formalin fixed paraffin embedded tissue samples.

Developed and validated the IHC biomarker panel for the Avastin clinical trial samples.

Developed and implemented comprehensive immunohistochemical techniques to include phage antibody, ligand-receptor binding, ScFv antibody and humanized antibody detection methods.

Conducted monoclonal antibody screening of hybridomas on both acute tissue sections and DNA transfected cell lines.

Other responsibilities included IHC training and consultations, management, website development and database maintenance.

Immunex (presently Amgen)– Seattle WA

1993-1997

Research Associate

Essential Job Functions:

Establish the histology and immunohistochemistry laboratories, procuring the necessary equipment and reagents to start up both laboratories.

Developed and validated immunohistochemistry protocols to evaluate CD30L expression in nonmalignant and Hodgkin’s disease-involved lymph nodes.

Developed and validated immunohistochemistry protocols to evaluate the spontaneous pneumocystis carinii infection in CD40 ligand-deficient mice.

Evaluated the skeletal defects, metabolic defects and placental disruptions in Leukemia Inhibitory Factor Receptor [LIFR] deficient mice.

Developed and validated PNA-Lectin immunohistochemistry protocols to evaluate the Humoral immune responses in CD40 ligand-deficient mice.

Conducted monoclonal antibody screening of hybridomas.

Performed small rodent necropsies and manipulations.

Technical consultant in mRNA and DNA in situ hybridization procedures.

Executed plastic/paraffin microtomy, cryomicrotomy and photomicrography

Children’s Hospital Medical Center - Seattle WA

1988-1993

Histotechnologist, Department of Pathology

Children’s Hospital Medical Center - Cincinnati, OH 1974-1984

Histotechnologist / Electron Microscopist, Department of Pathology

EDUCATION

Project Management Certificate, 2015: Everett Community College

Biological Sciences Course, 1980: University of Cincinnati, Cincinnati, OH

Medical Assistant Certification, 1971: Career Academy, Columbus, OH

Lean Six Sigma Green Belt Training, SNBL, USA, Ltd, Everett WA

Computer Validation for the Non-computer Professional, DIA, Everett WA

DAKO Advanced Automated Instrumentation Training: DAKO Santa Barbara CA

Ventana Advanced Automated Instrumentation Training: Ventana Medical, Tucson, AZ

Introduction to Flow Cytometry; Becton Dickinson; Milpitas, CA

Autoradiography in Electron Microscopy: Woods Hole Educational Associates

MEMBERSHIPS/PROFESSIONAL AFFILIATIONS AND CERTIFICATIONS

QIHC Certification: American Society of Clinical Pathology

HTL Certification: American Society of Clinical Pathology

HT Certification: American Society of Clinical Pathology

National Society for Histotechnology

PRESENTATIONS/PUBLICATIONS

“IVOS and Histopathology Procedures for GLP-Compliant Toxicology Studies in Nonhuman Primates.” R. Watson, D. Thompson, M. Novilla, N. Makori, R. Eyre, H. Tsusaki, and R. Nagata: Society of Toxicology 2011

“Spontaneous Endometriosis in a Naive Cynomolgus Macaque (Macaca fascicularis).” Kenichi Sato, Heather Sidener, Jeffery Engelhardt, Hideshi Tsusaki, Koichiro Fukuzaki and Ryoichi Nagata: Society of Toxicologic Pathologists 2010

“An Immunological Response Assessment to KLH Immunization in Infant Cynomolgus Monkeys.” N. Lalayeva, W. Komocsar, P. Lin, S. Oneda, N. Makori, A. Macintyre, R. Eyre, K. Fukuzaki, B. Baker, and R. Nagata: Society of Toxicology 2010

“A Bilateral Dystrophic Calcinosis Circumscripta in a Cynomolgus Macaque (Macaca fascicularis).” Kenichi Sato, Zaher A. Radi, Norbert Makori, Dale Morris, James Klaassen, Steven Meyer and Ryoichi Nagata: Society of Toxicologic Pathologists 2009

“IHC in Drug Development.” Barbara Wright, SNBL, USA Ltd 2009

“A Comparison of VEGF mRNA and HIF-1a Protein Expression in Tissue Microarrays.” Barbara Wright, Thinh Pham, Tom Wu, Patti Tobin, Gretchen Frantz and Kenneth Hillan. Asilomar Symposium, Pacific Grove, CA May 12-15, 2002

“Distribution and Expression in disease of a new family of molecules based on homology to JAM.” Daniel Tumas, Menno Van Lookeren, Austin Gurney, Tony Liang, Debra Dunlap, Gretchen Frantz, Barbara Wright and Sherman Fong. American College of Veterinary Pathology, Annual Meeting 2001

“CD40 Expression in Malignant Neoplasms: An Immunohistochemical Survey.” Barbara D. Wright, Patti Tobin and Hartmut Koeppen. Asilomar Symposium, Pacific Grove, CA September 24-28, 2000

“Immunohistochemical Applications and Techniques in a Veterinary/Biopharmaceutical Research Environment.” Barbara D. Wright. National Society for Histotechnology Annual Symposium. Milwaukee, Wisconsin September 16-21, 2000

“Incidence of Her2 Overexpression in Human Tumors: An Immunohistochemical Analysis Using a Standardized Automated Testing System.” Barbara D. Wright, Noel Dybdal, Kenneth J. Hillan, Hartmut Koeppen. National Society for Histotechnology Annual Symposium, Providence, Rhode Island October 16-21, 1999.

“Immunohistochemical Localization of Apo2L/TRAIL Protein in Paraffin-Embedded Tissues.” B.D. Wright; J. Kim; B. Pitti; H. Koeppen; K. J. Hillan. International Academy of Pathology, San Francisco, California March 20-26, 1999.

“Immunolocalization of Vascular Endothelial Growth Factor (VEGF) and Its Receptors (Flt-1 and KDR/Flk-1) Show Distinct Patterns in Normal Kidney.” Barbara D. Wright, Toni Klassen, Bruce Keyt, Kenneth J. Hillan, Anne M. Ryan and Belinda Cairns. Vascular Biology ’98, San Francisco, California April 15-18, 1998.

"Distinct function, phenotype and localization of lymphoid and myeloid dendritic cell subsets in Flt3-L treated mice." B. Pulendran, J. Lingappa, M. Kennedy, J. Smith, B. Wright, M. Teepe, A. Rudensky, D.E. Williams, C. Maliszewski and E. Maraskovsky. American Society of Hematology, Orlando, Florida, December 6-10, 1996.

"CD40 ligand-deficient mice: a new animal model for spontaneous pneumocystis carinii infection." JCL Schuh, KA Campbell, B Wright, K Harrington and W Fanslow. American College of Veterinary Pathologists, Seattle, Washington, December 2-6, 1996.

"Doxorubicin toxicity in mice: a model for chemotherapeutic-induced stomatitis/mucositis." J.C.L. Schuh, B.C. Gliniak and B.D. Wright. Society of Toxicologic Pathologists, 15th International Symposium in St. Louis, Missouri, June 9-13, 1996.

"The Absence of LIF Receptor Causes Defects in Placental Development and is a Perinatal Lethal." C.B. Ware, J.S. Hunt, C.R. Willis, B.R. Renshaw, B.D. Wright, D.P. Gearing, J.J. Peschon and B.L. Davison. BSDB/BSCB Spring Meeting, University of Edinburgh, April 5-8, 1994.

Katrina Nichols, Susan Guillet, Elizabeth Tomlinson, Kenneth Hillan, Barbara Wright, Gretchen D. Frantz, Thinh A Pham, Lisa Dillard-Telm, Siao Ping Tsai, Jean-Philippe Stephan, Jeremy Stinson, Timothy Stewart, and Dorothy French. A Mouse Model of Hepatocellular Carcinoma: Ectopic Expression of Fibroblast Growth Factor 19 in Skeletal Muscle of Transgenic Mice. American Journal of Pathology June 2002, 160(6): 2295-2307

Hartmut K.W. Koeppen, Barbara D. Wright, Noel O. Dybdal, Mark X Sliwkowski, Kenneth Hillan. Overexpression of HER2/neu in Solid Tumors: An Immunohistochemical Survey. Histopathology 2001, 38:96-104

Ilona N. Holcomb, Rhona C. Kabakoff, Austin Gurney, Thad Baker, Betty Chan, William Henzel, Barbara Wright, Gretchen Frantz, Franklin V. Peale, David L. Shelton, Daniel B. Tumas and Caroline C. Herbert. FIZZ1, A Novel Cysteine-rich Secreted Protein Related to Pulmonary Inflammation, Is a Member of a New Gene Family. EMBO J. 2000 Aug 1, 19(15): 4046-55.

Gerber HP. Hillan KJ. Ryan A. M. Kowalski J. Keller GA. Rangell L. Wright BD. Radtke F. Aguet M. Ferrara N. VEGF is required for Growth and Survival in Neonatal Mice. Development 126(6): 1149-59, 1999 March.

Gruss, H., Hirschstein, D., Wright, B., Ulrich, D., Caligiuri, M.A., Barcos, M., Strockbine, L., Armitage, R.J. and Dower, S.K. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 84:2305, 1994.

Renshaw, B., Fanslow, W.C., III, Armitage, R.J., Campbell, K. A., Liggitt, D., Wright, B., Davison, B. and Maliszewski, C.R. Humoral immune responses in CD40ligand-deficient mice. Journal of Experimental Medicine 180:1889, 1994.

Ware, C.B., Horowitz, M.C., Renshaw, B.R., Hunt, J.S., Liggitt, D., Koblar, S.A., Gliniack, B.C., McKenna, H.J., Papayannopoulou, T., Thoma, B., Cheng, L., Donovan, P.J., Peschon, J.J., Bartlett, P.F., Willis, C.R., Wright, B.D., Carpenter, M.K., Davison, B.L. and Gearing, D.P. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121:1283, 1995

Gruss, H.J., Pinto, A., Gloghini, A., Wehenes, E., Wright, B., Boiani, N., Aldinucci, D., Gattei, V., Zagonel, V., Smith, C.A., Kadin, M.E., Schilling, C.V., Goodwin, R.G., Herrmann, F. and Carbone, A. CD30 ligand expression in nonmalignant and Hodgkin's diseased-involved lymph nodes. American Journal of Pathology 149:469, 1996.



Contact this candidate